[go: up one dir, main page]

HUP0102602A2 - Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0102602A2
HUP0102602A2 HU0102602A HUP0102602A HUP0102602A2 HU P0102602 A2 HUP0102602 A2 HU P0102602A2 HU 0102602 A HU0102602 A HU 0102602A HU P0102602 A HUP0102602 A HU P0102602A HU P0102602 A2 HUP0102602 A2 HU P0102602A2
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compounds
independently
general formula
Prior art date
Application number
HU0102602A
Other languages
English (en)
Inventor
Christoph Gibson
Simon Goodman
Günter Hölzemann
Horst Kessler
Jörg Simon Schmitt
Original Assignee
Merck Patent Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh. filed Critical Merck Patent Gmbh.
Publication of HUP0102602A2 publication Critical patent/HUP0102602A2/hu
Publication of HUP0102602A3 publication Critical patent/HUP0102602A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány szerinti vegyületek (I) általános képletében X, Y és Zjelentése egymástól függetlenül szerves csoport, R1 és R2 jelentéseegymástól függetlenül hidrogénatom vagy alkilcsoport. A találmányezenkívül fenti (I) általános képletű vegyületek és/vagyfiziológiailag elfogadható sóik alkalmazása trombózis, szívinfarktus,szívkoronaér-megbetegedések, érelmeszesedés, tumorok, csontritkulás,gyulladások és fertőzések kezelésére szolgáló gyógyászati készítményelőállítására. A találmány tárgyköréhez tartoznak továbbá a fentivegyületek és hatóanyagként azokat tartalmazó gyógyászati készítményekelőállítására szolgáló eljárások. Ó
HU0102602A 1998-07-15 1999-07-06 Diacylhydrazine derivatives, method for their preparation, their use and pharmaceutical compositions comprising thereof HUP0102602A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19831710A DE19831710A1 (de) 1998-07-15 1998-07-15 Diacylhydrazinderivate
PCT/EP1999/004673 WO2000003973A1 (de) 1998-07-15 1999-07-06 Diacylhydrazinderivate als integrin-inhibitoren

Publications (2)

Publication Number Publication Date
HUP0102602A2 true HUP0102602A2 (hu) 2002-01-28
HUP0102602A3 HUP0102602A3 (en) 2002-02-28

Family

ID=7874107

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102602A HUP0102602A3 (en) 1998-07-15 1999-07-06 Diacylhydrazine derivatives, method for their preparation, their use and pharmaceutical compositions comprising thereof

Country Status (22)

Country Link
US (1) US6326403B1 (hu)
EP (1) EP1097127B1 (hu)
JP (1) JP2002520382A (hu)
KR (1) KR20010079520A (hu)
CN (1) CN1309633A (hu)
AR (1) AR019777A1 (hu)
AT (1) ATE234276T1 (hu)
AU (1) AU753333B2 (hu)
BR (1) BR9912072A (hu)
CA (1) CA2337305A1 (hu)
DE (2) DE19831710A1 (hu)
DK (1) DK1097127T3 (hu)
ES (1) ES2194486T3 (hu)
HU (1) HUP0102602A3 (hu)
ID (1) ID27168A (hu)
NO (1) NO20010203D0 (hu)
PL (1) PL345398A1 (hu)
PT (1) PT1097127E (hu)
SK (1) SK412001A3 (hu)
TW (1) TW448145B (hu)
WO (1) WO2000003973A1 (hu)
ZA (1) ZA200101267B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314315B1 (en) 1999-06-01 2015-01-21 Biogen Idec MA Inc. A blocking monoclonal antibody to the human alpha1 I-domain of VLA-1, and its use for the treatment of inflammatory disorders
PE20011222A1 (es) * 2000-04-14 2001-12-07 Abbott Lab Hidrazidas y alcoxiamidas inhibidoras de la angiogenesis
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
DE10040105A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften
DE10040103A1 (de) 2000-08-17 2002-02-28 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften II
DZ3415A1 (fr) * 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
DE60216747T2 (de) 2001-04-09 2007-10-04 Novartis Vaccines and Diagnostics, Inc., Emeryville Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
AR036330A1 (es) 2001-04-13 2004-09-01 Biogen Inc Un anticuerpo anti-vla-1, una composicion que lo incluye, un acido nucleico aislado consistente en una secuencia de codificacion de dicho anticuerpo, un metodo para determinar el nivel de vla-1 en un tejido, celulas del hibridoma de dicho anticuerpo, una computadora que produce una representacion tr
MXPA04011557A (es) 2002-05-23 2005-07-05 Chiron Corp Compuestos de quinazolinona sustituida.
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
US7304161B2 (en) * 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
EP1651229A1 (en) 2003-05-23 2006-05-03 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
DE10325049A1 (de) * 2003-06-02 2004-12-23 Merck Patent Gmbh Peptid- und Peptidmimetika-Derivate mit Integrin-Inhibitor-Eigenschaften III
WO2005051391A1 (en) 2003-11-19 2005-06-09 Chiron Corporation Quinazolinone compounds with reduced bioaccumulation
EP2484365B1 (en) 2004-06-04 2013-10-02 The Scripps Research Institute Compositions and method for treatment of neovascular diseases
JP4745175B2 (ja) * 2005-12-28 2011-08-10 本田技研工業株式会社 自動二輪車
ES2509878T3 (es) 2006-05-25 2014-10-20 Biogen Idec Ma Inc. Anticuerpo anti-VLA-1 para tratar accidente cerebrovascular
NZ582013A (en) 2007-05-29 2012-03-30 Intrexon Corp Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
US9127024B2 (en) 2013-03-15 2015-09-08 Intrexon Corporation Boron-containing diacylhydrazines
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
CN104027805B (zh) * 2014-06-18 2017-02-15 北京大学 抑制整合素α5的物质在制备预防内皮细胞激活和/或动脉粥样硬化的产品中的新用途
SG11201701944WA (en) 2014-09-17 2017-04-27 Intrexon Corp Boron-containing diacylhydrazine compounds
SG11202002967SA (en) 2017-11-01 2020-05-28 Arrowhead Pharmaceuticals Inc Integrin ligands and uses thereof
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
EP0570507A4 (en) * 1991-02-05 1994-09-21 Smithkline Beecham Corp Anti-aggregatory peptides containing an aromatic ester or amide
US5530028A (en) * 1992-11-23 1996-06-25 Rohm And Haas Company Insecticidal N'-substituted-N,N'-diacylhydrazines
JPH08505846A (ja) * 1992-12-29 1996-06-25 スミスクライン・ビーチャム・コーポレイション 血小板凝集阻害用化合物
JPH10501222A (ja) 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
US5482962A (en) * 1994-07-22 1996-01-09 Rohm And Haas Company Insecticidal N,N'-disubstituted-N-N'-diacylhydrazines
EP0880511A4 (en) * 1996-01-16 1999-06-16 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
EP1097127A1 (de) 2001-05-09
KR20010079520A (ko) 2001-08-22
US6326403B1 (en) 2001-12-04
NO20010203L (no) 2001-01-12
PL345398A1 (en) 2001-12-17
AR019777A1 (es) 2002-03-13
DE59904547D1 (de) 2003-04-17
NO20010203D0 (no) 2001-01-12
TW448145B (en) 2001-08-01
ZA200101267B (en) 2002-10-04
DK1097127T3 (da) 2003-06-10
AU753333B2 (en) 2002-10-17
ES2194486T3 (es) 2003-11-16
CA2337305A1 (en) 2000-01-27
HUP0102602A3 (en) 2002-02-28
CN1309633A (zh) 2001-08-22
EP1097127B1 (de) 2003-03-12
DE19831710A1 (de) 2000-01-20
ATE234276T1 (de) 2003-03-15
BR9912072A (pt) 2001-09-25
WO2000003973A1 (de) 2000-01-27
JP2002520382A (ja) 2002-07-09
SK412001A3 (en) 2001-08-06
AU5031399A (en) 2000-02-07
ID27168A (id) 2001-03-08
PT1097127E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
HUP0102602A2 (hu) Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
HUP0002104A2 (hu) Pirazolo[3,4-d]pirimidindion-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
BR9711135A (pt) Composto composi-Æo farmac-utica utiliza-Æo de um composto e processos para prepara-Æo de um composto e para inibi-Æo de Äxido-equaleno ciclase num animal de sangue quente requerendo um tal tratamento
ATE316083T1 (de) Adamantanderivate
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
HUP0103063A2 (hu) Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására
MXPA04000577A (es) Derivados de dolastatina 10.
CA2207835A1 (fr) Nouveaux derives du 3-(piperid-4-yl) 1,2-benzisoxazole et du 3-(piperazin-4-yl) 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
NO991384L (no) Substituerte heterocykler som anti-tumormidler
EP0992509A3 (en) Novel macrolide derivatives
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
HUP0002683A2 (hu) Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek
BG106155A (en) Novel derivatives and analogues of galanthamin
HUT51221A (en) Process for producing pharmaceutical compositions comprising 3-demethyl-4-fluoromevalonic acid derivatives and the active ingredients
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
HUP9802897A2 (hu) Optikailag aktív piridil-4H-1,2,4-oxadiazin-származék, annak alkalmazása vaszkuláris betegségek kezelésére, valamint ilyen származékot hatóanyagként tartalmazó gyógyászati készítmény
MX9708735A (es) Benzotiazoles y benzoxazoles, composiciones farmaceuticas que contienen estos compuestos y su uso y proceso para prepararlos.
HUP0001773A2 (hu) Szubsztituált tetrahidropiridinszármazékok, eljárás előállításukra, továbbá a vegyületeket tartalmazó gyógyászati készítmények
YU31995A (sh) Benzotiofeni glikopiranozida, postupak za njihovo dobijanje i njihova farmaceutska formulacija
HUP0004701A2 (hu) Új dezloratadin sók, az ezeket tartalmazó gyógyászati készítmények és eljárás azok előállítására
HUP0104533A2 (hu) Új pirimidinszármazékok és eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények